62028 20200221144349.0 doi 10.1515/cclm-2015-0821 sideral 95040 ART-2016-95040 eng Sanchis-Gomar, F. Galectin-3, osteopontin and successful aging 2016 Access copy available to the general public Unrestricted Background: Individuals who reach exceptional longevity (100+ years of age) free of common chronic age diseases (i.e. ''dodgers'') arguably represent the paradigm of successful aging in humans. As such, identification of potential biomarkers associated with this phenomenon is of medical interest. Methods: We measured serum levels of galectin-3 and osteopontin, both of which have been shown to be linked with major chronic or aging-related disorders in younger populations, in centenarian ''dodgers'' (n=81; 40 men; 100-104 years) and healthy controls (n=41; 24 men, 70-80 years). Results: Both biomarkers showed significantly lower values (p<0.001) in the former (galectin-3: 2.4±1.7 vs. 4.8±2.8 ng/mL; osteopontin: 38.1±27.7 vs. 72.6±33.1 µg/mL). Logistic regression analysis identified the combination of these two biomarkers as a significant predictor variable associated with successful aging regardless of sex (p<0.001). The area under the curve (AUC) classified the ability of galectin-3 and osteopontin to predict the likelihood of successful aging as ''fair'' (AUC=0.75) and ''good'' (AUC=0.80), respectively. Particularly, the combination of the two biomarkers showed good discriminatory power for successful aging (AUC=0.86), with sensitivity=83% and specificity=74%. Conclusions: Lower levels of both galectin-3 and osteopontin are associated with successful aging, representing potential biomarkers of this condition. Our cross-sectional data must be however approached with caution. Further research is necessary to replicate the present preliminary results in other cohorts and to identify the potential use of galectin-3 and osteopontin as potential targets (or at least predictors) in future personalized anti-aging therapies. info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 3.432 2016 MEDICAL LABORATORY TECHNOLOGY 5 / 30 = 0.167 2016 Q1 T1 1.038 2016 Biochemistry (medical) 2016 Q1 Medicine (miscellaneous) 2016 Q1 Clinical Biochemistry 2016 Q2 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Santos-Lozano, A. Pareja-Galeano, H. (orcid)0000-0001-8374-9081 Garatachea, N. Universidad de Zaragoza Alis, R. Fiuza-Luces, C. Morán, M. Emanuele, E. Lucia, A. 1006 245 Universidad de Zaragoza Dpto. Fisiatría y Enfermería Área Educación Física y Depor. 54, 5 (2016), 873-877 Clin. chem. lab. med. Clinical Chemistry and Laboratory Medicine 1434-6621 692214 http://zaguan.unizar.es/record/62028/files/texto_completo.pdf Versión publicada 127498 http://zaguan.unizar.es/record/62028/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:62028 articulos driver 2020-02-21-13:54:10 ARTICLE